

Medical Countermeasures against Nuclear Threats: Decorporation Agents *Agenda*

September 17 - 18, 2007

Division of Allergy, Immunology and Transplantation (DAIT),
National Institute of Allergy and Infectious Diseases (NIAID)
National Institutes of Health (NIH)

Bethesda Marriott
5151 Pooks Hill Road
Bethesda, MD

Day 1: Monday, September 17, 2007

- 8:00 a.m. Arrival/Sign In/Refreshments
- 8:30 a.m. **Welcome and Goals of the Meeting**
Dr. Bert Maidment, DAIT, NIAID, NIH, Bethesda, MD
Dr. David Cassatt, DAIT, NIAID, NIH, Bethesda, MD
- 8:35 a.m. **Opening Remarks**
Dr. Richard Hatchett, DAIT, NIAID, NIH, Bethesda, MD
- 8:40 a.m. **Development and Acquisition of High Priority Radionuclide Medical Countermeasures –
HHS/BARDA Roles and Responsibilities**
Dr. Joanna Prasher, DHHS

Overview and Needs

- 9:10 a.m. **Health Effects of Radionuclides and Current Treatments**
Dr. Albert Wiley, REAC/TS
- 9:40 a.m. Discussion
- 9:50 a.m. **BREAK**
- 10:10 a.m. **Radionuclide Chelation Animal Experiments and Animal Models, Biokinetics of
Radionuclides and Calculation of Whole-Body/Tissue Committed Dose**
Dr. Raymond Guilmette, LANL
- 10:55 a.m. Discussion



Medical Countermeasures against Nuclear Threats: Decorporation Agents

Agenda

- 11:05 a.m. **Radiological Dispersal Devices: Physically Based Dispersal Characteristics and Limitations**
Dr. Fred Harper, Sandia National Laboratory
- 11:35 a.m. Discussion
- 11:45 p.m. **LUNCH**

Pathway to Licensure

- 1:00 p.m. **Licensure of Radionuclide Chelating Agents**
Dr. Narayan Nair, FDA
- 1:40 p.m. Discussion
- 1:50 p.m. **BREAK**

DTPA Contracts

- 2:10 p.m. **Development of Improved DTPA for Radionuclide Chelation: Prodrug Approach**
Dr. Michael Jay, University of Kentucky
- 2:40 p.m. Discussion
- 2:50 p.m. **Development of Improved DTPA for Radionuclide Chelation: Transport Enhancers**
Dr. Gita Shankar, SRI International
- 3:20 p.m. Discussion
- 4:00 p.m. **ADJOURN**



Medical Countermeasures against Nuclear Threats: Decorporation Agents *Agenda*

Day 2: Tuesday, September 18, 2007

8:00 a.m. Arrival/Refreshments

Chelating Agents

8:30 a.m. **Polonium-210 and Sulfhydryl Chelating Agents**

Dr. H. Vasken Aposhian, University of Arizona

9:00 a.m. Discussion

09:10 a.m. **Use of Sypine® and Cuprimine®, FDA-Approved Therapeutics for Wilson's Disease, as Oral Radioisotope Decorporation Agents**

Dr. Barry Levinson, Aton Pharma, Inc.

09:40 a.m. Discussion

Novel Chelators Grants

9:50 a.m. **Desferrithiocin Analogue Actinide Decorporation Agents**

Dr. Raymond Bergeron, University of Florida

10:20 a.m. Discussion

10:30 a.m. **BREAK**

10:40 a.m. **Biomimetic Lanthanide & Actinide Decorporation Agents: Preclinical Development**

Dr. Kenneth Raymond, UC Berkeley/LBNL

11:10 a.m. Discussion

11:20 a.m. **Amphipathic Oral Chelators and Radionuclide Contamination**

Dr. Scott Miller, University of Utah

11:50 a.m. Discussion

12:00 p.m. **LUNCH**

1:00 p.m. **Biomaterials as Decorporation Agents for Radionuclides**

Dr. Tatiana Levitskaia, PNNL

1:30 p.m. Discussion



Medical Countermeasures against Nuclear Threats: Decorporation Agents *Agenda*

- 1:40 p.m. **Development of Selective Nanoporous Sorbents for Radionuclide Decorporation**
Dr. Charles Timchalk, PNNL
- 1:50 p.m. Discussion
- 2:30 p.m. Closing Remarks
- 2:45 p.m. **WORKSHOP ADJOURNED**

